Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6731406 | 0.86 | GRM2 (0.55) | MAPTTP53CYP3A4TSHRHTT | |
| SCHEMBL6739041 | 0.85 | CYP3A4 (0.50) | MAPTTP53CYP3A4TSHRHTT | |
| SCHEMBL6730973 | 0.85 | MAPT (0.51) | MAPTTP53CYP3A4MAPK1GRM2 | |
| SCHEMBL6733035 | 0.84 | MAPT (0.54) | MAPTTP53CYP3A4LMNATSHR | |
| SCHEMBL6739403 | 0.82 | MAPT (0.51) | MAPTTP53CYP3A4LMNAPOLB | |
| SCHEMBL7419432 | 0.82 | CYP3A4 (0.49) | MAPTTP53CYP3A4LMNATSHR | |
| SCHEMBL6730921 | 0.82 | NR1H4 (0.46) | MAPTTP53CYP3A4LMNAALDH1A1 | |
| SCHEMBL6727717 | 0.81 | CYP19A1 (0.48) | MAPTTP53CYP3A4GRM2 | |
| SCHEMBL6735083 | 0.81 | GRM2 (0.50) | RAB9AMAPTTP53CYP3A4MAPK1 | |
| SCHEMBL6733385 | 0.81 | CYP3A4 (0.47) | MAPTTP53CYP3A4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | NPC1 1454/4885RAB9A 2810/4885MAPT 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.